Intellia Therapeutics (NTLA) Profit After Tax (2015 - 2026)
Intellia Therapeutics (NTLA) reported Profit After Tax of -$96.2 million for Q1 2026, up 15.83% year-over-year from -$83.1 million in Q1 2025, and little changed on a QoQ basis from -$95.8 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Profit After Tax data on file, last reported at -$96.2 million in Q1 2026.
- Quarterly Profit After Tax rose 15.83% year-over-year to -$96.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$394.6 million (up 24.97% YoY) and the FY2025 annual result came in at -$412.7 million, up 20.49% from the prior year.
- Profit After Tax held at -$96.2 million in Q1 2026 per NTLA's latest filing, from -$95.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$95.8 million in Q4 2025 and bottomed at -$147.0 million in Q2 2024.
- The 5-year median for Profit After Tax is -$113.4 million (2022), against an average of -$116.7 million.
- The widest annual swing landed in 2022, when Profit After Tax sank 217.87%; it then jumped 31.11% in 2025.
- Tracing NTLA's Profit After Tax over 5 years: stood at -$113.4 million in 2022, then decreased by 16.54% to -$132.2 million in 2023, then rose by 2.47% to -$128.9 million in 2024, then grew by 25.69% to -$95.8 million in 2025, then dropped by 0.46% to -$96.2 million in 2026.
- Per Business Quant, the three latest NTLA Profit After Tax figures stand at -$96.2 million (Q1 2026), -$95.8 million (Q4 2025), and -$101.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -96.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.23 Mn |
| Dec 31, 2025 | -95.79 Mn |
| Sep 30, 2025 | -101.32 Mn |
| Jun 30, 2025 | -101.26 Mn |
| Mar 31, 2025 | -114.33 Mn |
| Dec 31, 2024 | -128.90 Mn |
| Sep 30, 2024 | -135.71 Mn |
| Jun 30, 2024 | -146.98 Mn |
| Mar 31, 2024 | -107.44 Mn |
| Dec 31, 2023 | -132.16 Mn |
| Sep 30, 2023 | -122.22 Mn |
| Jun 30, 2023 | -123.68 Mn |
| Mar 31, 2023 | -103.13 Mn |
| Dec 31, 2022 | -113.41 Mn |
| Sep 30, 2022 | -113.23 Mn |
| Jun 30, 2022 | -100.68 Mn |
| Mar 31, 2022 | -146.87 Mn |
| Dec 31, 2021 | -81.24 Mn |
| Sep 30, 2021 | -71.64 Mn |
| Jun 30, 2021 | -68.81 Mn |
| Mar 31, 2021 | -46.21 Mn |
| Dec 31, 2020 | -42.19 Mn |
| Sep 30, 2020 | -27.84 Mn |
| Jun 30, 2020 | -32.39 Mn |
| Mar 31, 2020 | -31.81 Mn |
| Dec 31, 2019 | -28.28 Mn |
| Sep 30, 2019 | -23.63 Mn |
| Jun 30, 2019 | -25.68 Mn |
| Mar 31, 2019 | -21.94 Mn |
| Dec 31, 2018 | -19.07 Mn |
| Sep 30, 2018 | -22.70 Mn |
| Jun 30, 2018 | -22.22 Mn |
| Mar 31, 2018 | -21.36 Mn |
| Dec 31, 2017 | -23.96 Mn |
| Sep 30, 2017 | -15.36 Mn |
| Jun 30, 2017 | -15.59 Mn |
| Mar 31, 2017 | -12.63 Mn |
| Dec 31, 2016 | -10.56 Mn |
| Sep 30, 2016 | -7.48 Mn |
| Jun 30, 2016 | -6.90 Mn |
| Mar 31, 2016 | -6.69 Mn |
| Dec 31, 2015 | -5.25 Mn |
| Sep 30, 2015 | -3.02 Mn |
| Jun 30, 2015 | -3.04 Mn |
| Mar 31, 2015 | -1.09 Mn |